---
title: "Oncology Institute - CW22 | 8-K: FY2025 Q1 Revenue: USD 104.41 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240231942.md"
datetime: "2025-05-14T20:26:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240231942.md)
  - [en](https://longbridge.com/en/news/240231942.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240231942.md)
---

# Oncology Institute - CW22 | 8-K: FY2025 Q1 Revenue: USD 104.41 M

Revenue: As of FY2025 Q1, the actual value is USD 104.41 M.

EPS: As of FY2025 Q1, the actual value is USD -0.21.

### Segment Revenue

-   **Consolidated Revenue**: $104.4 million, an increase of 10.3% from $94.7 million compared to the prior year quarter.
-   **Patient Services Revenue**: $53.1 million, up 1.2% compared to Q1 2024.
-   **Dispensary Revenue**: $49.3 million, an increase of 24.2% compared to Q1 2024.

### Operational Metrics

-   **Gross Profit**: $17.2 million, an increase of 44.1% compared to the prior year quarter.
-   **Net Loss**: $19.6 million compared to $19.9 million for the prior year quarter.
-   **Adjusted EBITDA**: - $5.1 million compared to - $10.9 million for the prior year quarter.
-   **SG&A Expenses**: $25.4 million or 24.3% of revenue, compared with $28.5 million or 30.1% of revenue in Q1 2024.

### Cash Flow

-   **Net Cash and Cash Equivalents Used in Operating Activities**: - $5.0 million for Q1 2025.
-   **Free Cash Flow**: - $4.0 million, compared to - $15.4 million in Q1 2024.

### Unique Metrics

-   **Retail Pharmacy and Dispensary Revenue**: $49.3 million, contributing over $9 million in gross profit in Q1.

### Outlook / Guidance

-   The Oncology Institute reaffirms its full year 2025 guidance with expected revenue between $460 to $480 million, gross profit between $73 to $82 million, adjusted EBITDA between - $8 to - $17 million, and free cash flow between - $12 to - $21 million.
-   The company anticipates new capitation contracts in the first half of 2025 projected to add approximately $50 million in new revenue on an annualized basis.
-   TOI expects adjusted EBITDA of approximately - $4 to - $5 million in the second quarter of 2025 due to stabilization of contracts and initial lower encounter volumes.

### Related Stocks

- [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md)
- [STLNW.US](https://longbridge.com/en/quote/STLNW.US.md)